Navigation Links
Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Mutation Tests
Date:6/2/2008

Tests identify genetic mutations that can affect patient response to

certain cancer drugs

PLEASANTON, Calif., June 2 /PRNewswire/ -- Roche and DxS Ltd. have signed an exclusive distribution agreement for the DxS TheraScreen K-RAS Mutation Test and TheraScreen EGFR 29 Mutation Test. The tests are intended, when considered with other clinically relevant factors, to aid doctors in identifying suitable patients likely to benefit from a specific cancer therapy based on their mutation status.

"There is a growing demand for tests to indicate disease prognosis and identify patient groups more likely to benefit from a particular drug," said Daniel O'Day, President and CEO of Roche Molecular Diagnostics. "Through our partnership with DxS, we can leverage our extensive global infrastructure and commercial reach to provide these tests, which have the potential to improve treatment outcome in some patients."

Under the terms of the agreement, Roche is granted exclusive world-wide distribution rights for the K-RAS Test, which has CE Mark certification in Europe. For the EGFR test, which also has CE Mark certification, Roche is granted exclusive distribution rights for all global markets except the United States, Canada, Mexico, and Hong Kong.

"We are extremely pleased to have concluded this distribution agreement with Roche," said Dr. Stephen Little, CEO of DxS Ltd. "Not only does it enable us to meet the growing demand for these tests, but also gives doctors and patients access to standardized test results that provide further information to enhance treatment decisions."

The TheraScreen K-RAS Mutation Test was the first clinically validated, CE-Mark certified companion diagnostic for tumor-specific mutations in patients with colorectal cancer. In addition, some drugs used to treat colorectal and other cancers are only indicated for patients who have a non- mutated (or "wild-type") K-RAS gene. The test detects
'/>"/>

SOURCE Roche Molecular Diagnostics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
2. Roche Extends Tender Offer for Ventana
3. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
4. Roche Real-Time HIV Test is Faster and Less Labor-Intensive Than Competitors
5. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
6. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
7. Med Ad News Honors Roche as Company of the Year
8. MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City
9. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
10. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
11. Kosan to Reacquire Epothilone Program From Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 25, 2014 Silicon Valley Electronic ... with RPM Alliance , provider of clinical research ... With the latest addition to its CRO Partnership Program, ... EDC system to India. , “We have found ... and customizable EDC platform which is both user friendly ...
(Date:11/26/2014)... SoundConnect , an award winning ... announce that Darren Suders has joined the team as ... drive the partner program through innovative offerings, ... , Darren brings more than 10-years of channel telecommunication ... channel operations, from policy development, to partner education and ...
(Date:11/26/2014)... -- Theravalues Corporation annuncia con orgoglio il lancio di ... Hi Europe 2014 (dal 2 al 4 dicembre, ... curcumina con la maggiore biodisponibilità di sempre, con una ... dalle norme europee. La curcumina è un ... Curcuma longa ) che è stata associata con attività ...
(Date:11/24/2014)... , Nov. 24, 2014 VolitionRx Limited ... tests for cancer and other conditions, today announced that data ... the Science for Business BioWin Day 2014, being held November ... data come from VolitionRx,s lung cancer pilot study, the samples ... Centre Hospitalier Universitaire (CHU) de Liege in Belgium ...
Breaking Biology Technology:RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6
... Calif., Jan. 22 Abaxis, Inc.,(Nasdaq: ABAX ), ... scheduled a conference call to discuss its,financial results for ... 2007. The call will be at 4:15 p.m. ET, ... 356-5706 or (706) 643-0580 to access the,conference call, or ...
... 8:30 a.m. EST at ... http://www.isispharm.com , ... ) announced today that Abbott is,investing up to $40 million in ... further develop the Ibis T5000(TM),Biosensor System, which offers a unique solution ...
... Marker Precision and ... Simultaneous Diagnostic Monitoring MUKILTEO, Wash. ... CBMX ) and Clarient, Inc. (Nasdaq: CLRT ),today ... a novel genomics-based cancer test called HemeScan(TM), a,comprehensive test related ...
Cached Biology Technology:Abaxis to Report Third Quarter Fiscal 2008 Financial Results Thursday, January 31, 2008 2Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity 2Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity 3Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity 4CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 2CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 3CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 4CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 5CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 6
(Date:11/4/2014)... – University of Utah engineers developed the first room-temperature ... produce electricity without needing to ignite the fuel. These ... electronics, off-grid power and sensors. , A study of ... Chemical Society journal ACS Catalysis . , Fuel ... between a fuel and an oxygen-rich source such as ...
(Date:11/4/2014)...   3D scanner ... Fuel3D , a developer of 3D scanning solutions, ... $6.4 million (£4 million). This funding builds on the company,s ... and paves the way for the commercial launch of the ... round was led by Chimera Partners and will be used ...
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® , ... life sciences company focused on commercialization of its ... for the treatment of neurological and neuropsychiatric disorders, ... Property has issued a Notice of Allowance for ... is co-owned by NeuroSigma and the Regents of ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... Although the soluble factor TGF-beta has been shown to suppress ... breast cancer, high levels of TGF-beta during the later stages ... study using human breast cancer samples and mice, which appears ... January print issue of the Journal of Clinical Investigation, indicates ...
... successfully tested two candidate vaccines that may eventually be ... Their findings are published in the December 15 issue ... , Barney S. Graham, MD, PhD, and colleagues from ... in Maryland, the Fred Hutchinson Cancer Research Center in ...
... the University of Rochester may have answered one of ... neurons, which are responsible for our crystal-clear thoughts, seem ... November issue of Nature Neuroscience, the Rochester study shows ... signals to represent the ambiguities of the real world--and ...
Cached Biology News:Progress made in HIV vaccine development 2Mysterious 'neural noise' actually primes brain for peak performance 2Mysterious 'neural noise' actually primes brain for peak performance 3
Mouse BLC/BCA 1 - 10kDa...
Bag-1 (K-20)...
... PGE2-d4 contains 4 deuterium atoms at ... It is intended for use as an ... E2 (PGE2) by GC- or LC-mass spectrometry. ... products of arachidonic acid and one of ...
Deletions, insertions or substitutions. Mutations in plasmids of size up to 15 kb. Single or multiple mutations...
Biology Products: